Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 14/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.39 |
| ▸ | FAP | Q12884 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1491556 | 1.00 | DPP4 (0.46) | DPP4EPHX1CYP19A1DPP7KCNH2 | |
| SCHEMBL8203394 | 1.00 | DPP4 (0.46) | DPP4EPHX1CYP19A1DPP7KCNH2 | |
| SCHEMBL18075666 | 0.94 | CYP19A1 (0.42) | DPP4EPHX1CYP19A1DPP7L3MBTL1 | |
| SCHEMBL18075665 | 0.94 | CYP19A1 (0.42) | DPP4EPHX1CYP19A1DPP7L3MBTL1 | |
| SCHEMBL770738 | 0.82 | CYP19A1 (0.50) | EPHX1CYP19A1L3MBTL1 | |
| SCHEMBL38556 | 0.82 | CYP19A1 (0.50) | EPHX1CYP19A1L3MBTL1 | |
| SCHEMBL18630281 | 0.82 | CYP19A1 (0.50) | EPHX1CYP19A1L3MBTL1 | |
| SCHEMBL16554167 | 0.82 | CYP19A1 (0.50) | EPHX1CYP19A1L3MBTL1 | |
| SCHEMBL16373577 | 0.82 | CYP19A1 (0.50) | EPHX1CYP19A1L3MBTL1 | |
| SCHEMBL16554168 | 0.82 | CYP19A1 (0.50) | EPHX1CYP19A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4687866-A1 | INHIBITORS OF ETS2-ACTIVATING MOLECULES FOR THE TREATMENT OF INFLAMMATORY DISEASES | The Francis Crick Institute Limited (GB) | 2026-02-11 | — | — | EP | claimed |
| WO-2024208705-A1 | INHIBITORS OF ETS2-ACTIVATING MOLECULES FOR THE TREATMENT OF INFLAMMATORY DISEASES | THE FRANCIS CRICK INSTITUTE LIMITED (GB) | 2024-10-10 | — | — | WO | claimed |
| EP-4687866-A1 | INHIBITORS OF ETS2-ACTIVATING MOLECULES FOR THE TREATMENT OF INFLAMMATORY DISEASES | The Francis Crick Institute Limited (GB) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024208705-A1 | INHIBITORS OF ETS2-ACTIVATING MOLECULES FOR THE TREATMENT OF INFLAMMATORY DISEASES | THE FRANCIS CRICK INSTITUTE LIMITED (GB) | 2024-10-10 | — | — | WO | disclosed |
| EP-2013175-B9 | p38 MAP KINASE INHIBITORS | MACROPHAGE PHARMA LTD (GB) | 2020-11-11 | — | — | EP | disclosed |
| EP-2069291-B1 | HDAC INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2017-12-20 | — | — | EP | disclosed |
| US-9725407-B2 | HDAC inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-08-08 | — | — | US | disclosed |
| US-9725407-B2 | HDAC inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-08-08 | — | — | US | disclosed |
| EP-2013175-B1 | p38 MAP KINASE INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2016-11-09 | — | — | EP | disclosed |
| US-20160137594-A1 | HDAC INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2016-05-19 | — | — | US | disclosed |
| US-20160137594-A1 | HDAC INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2016-05-19 | — | — | US | disclosed |
| WO-2008053131-A1 | HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | CHROMA THERAPEUTICS LTD. (GB) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008050078-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008040934-A1 | HDAC INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2008-04-10 | — | — | WO | disclosed |
| CN-101133060-A | Enzyme inhibitors | CHROMA THERAPEUTICS LTD (GB) | 2008-02-27 | — | — | CN | disclosed |
| EP-1879895-A1 | ENZYME INHIBITORS | Chroma Therapeutics Limited (GB) | 2008-01-23 | — | — | EP | disclosed |
| WO-2007129048-A1 | THIAZOLE DERIVATIVES AS INHIBITORS OF P13 KINASE | CHROMA THERAPEUTICS LTD. (GB) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007129040-A1 | p38 MAP KINASE INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2007-11-15 | — | — | WO | disclosed |
| WO-2006117549-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006117549-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137594-A1 | HDAC INHIBITORS | HDAC1, HDAC11, HDAC2 | DPP4 3070/4885EPHX1 4052/4885CYP19A1 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.